Contact UsEN简繁

WuXi AppTec

Global Platform
One Vision

Our Vision

Every Drug Can Be Made
and Every Disease Can Be Treated

By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry

Our Values

Integrity & Dedication, Working Together & Sharing Success;
Doing the Right Thing, Doing It Right.

About Us

Enabling Innovation

Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."

Services and Solutions

An Open Enabling Platform

Enabling more than 3,600 Innovative Collaborators from more than 30 Countries

icon

Small Molecule Drug R&D and Manufacturing

icon

Cell Therapy
and Gene Therapy

icon

Drug R&D and Medical
Device Testing

icon

Clinical
Services

icon

Small Molecule Drug R&D and Manufacturing

Company Platform

Enabling Anyone, Any Company

To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry

Research Service Division

Providing comprehensive
end-to-end drug discovery solutions

Laboratory Testing Division

Providing integrated testing solutions for drug development and medical device innovation

STA Pharmaceutical

Global leading platform for pharmaceutical development and manufacturing

Advanced Therapies Unit

Cell therapy and gene therapy R&D and production platform

WuXi Clinical

Providing global clinical development solutions, with dedicated resources in 60+ countries

WuXi SMO

Clinical trial site operation for Phase I-IV pharmaceutical and medical device study

LabNetwork

Global e-commerce platform linking R&D products, suppliers and buyers

News

The Latest News about WuXi AppTec

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery

WuXi AppTec Reports First Half 2019 Interim Results

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies

WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

SHANGHAI, CHINA; CAMBRIDGE, MASSACHUSETTS, USA; SANKT AUGUSTIN, GERMANY Oct 10, 2019 - WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec’s library of novel drug-like scaffolds, GalaXi® offers access to billions of compounds to drug discoverers around the world. Due to a carefully selected building block supply and proven chemistry, the GalaXi® space consists of molecules that can be quickly synthesized on demand.

Read more

WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery

SHANGHAI, BOSTON, Sep. 3, 2019 - WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit finding services to expedite early drug discovery and bring new medicines to patients faster.

Read more

WuXi AppTec Reports First Half 2019 Interim Results

SHANGHAI, August 19, 2019— WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a platform that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its financial results for the six months ended June 30, 2019 (“Reporting Period”).

Read more

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

SHANGHAI, 23 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the U.S. Food and Drug Administration (FDA) within the same week, with no Form 483s issued. This not only marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture, but also shows its commitment on providing integrated R&D and manufacturing services with the highest quality standard for customers.

Read more

WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies

SHANGHAI, June 29, 2019 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its dedication in building an open-access R&D enabling platform for companies around the world to discover and develop new medicines for patients efficiently.

Read more

WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.

Read more

Careers

Welcome to

Our Team

Become Part of Creating a Better Life

Investors

The Latest Financial Reports, Announcements and Resources